WinSanTor: Developing The First Disease Modifying Drug to Regenerate Peripheral Nerves

1

Drug regenerating peripheral nerves (humans) - combating direct cause of peripheral neuropathy

2

Repurposed medication w/ UNPARALLELED safety profile in FINAL phase (PH3) of clinical studies (DPN)

3

UNMET need affecting 100s of millions, ignored/neglected by industry, e.g., few, if any, competitors

4

VALIDATED science rewarded by innovation grants (>$40M) and licensing deal (>$200M + royalty)

5

Strong economic MOAT (the top KOLs, patents & other intellectual property, partners and strategy)

6

CEO's past companies were snatched by tech giants Qualcomm and Apple, tech now standards in industry

7

Industry ICONS lead our board, driving disruptive and transformative changes in healthcare

8

LAST crowdfunding investment opportunity before drug approval and IPO (~2-3 years)

WinSanTor was not started as a typical company. Similar to the COVID story (infectious diseases), peripheral neuropathy was neglected by industry (and investors). The leading stakeholders gathered and funded the top researchers in DPN to find solutions. We were lucky. They just happened to discover a way to regenerate nerves, thus WST.

WinSanTor

Developing The First Disease Modifying Drug to Regenerate Peripheral Nerves

$728,502

Highlights

Our Team

Pitch